FSD Pharma Inc. (HUGE) |
| 0.0899 -0.01 (-10.1%) 08-14 16:00 |
| Open: | 0.095 |
| High: | 0.1042 |
| Low: | 0.087 |
| Volume: | 22,015,006 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.01 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 23.81 |
| Resistance 1: | 14.75 |
| Pivot price: | 4.47 |
| Support 1: | 0.09 |
| Support 2: | 0.07 |
| 52w High: | 109.1935 |
| 52w Low: | 0.087 |
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Financials
| EPS | -16.250 |
| Book Value | 17.090 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -36.5 |
| Return on Equity (ttm) | -63.9 |
Company news
Tue, 08 Apr 2025
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc. - ACCESS Newswire
Thu, 15 Aug 2024
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM" - Stock Titan
Fri, 09 Aug 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team - Yahoo Finance
Fri, 09 Aug 2024
FSD Pharma Announces Share Consolidation and Name Change - Stock Titan
Mon, 01 Jul 2024
About Us - FinancialContent
Fri, 28 Jun 2024
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd. - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
